AC Immune (ACIU) COO Piergiorgio Donati reports shares and long-dated options

Rhea-AI Filing Summary

AC Immune SA Chief Operating Officer Piergiorgio Donati filed an initial ownership report detailing his equity position. He directly holds 141,120 common shares, which include 136,620 common shares underlying outstanding restricted share units. In addition, he reports multiple share options over common shares with exercise prices between $2.03 and $9.50 per share and expiration dates from July 2028 through December 2035. Some options are already fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026, providing a staggered schedule of potential future share deliveries.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Donati Piergiorgio

(Last) (First) (Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE 1015

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/20/2026

3. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	141,120(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(2)	07/05/2028	Common Shares	7,200	$9.5	D
Share Option (right to buy)	(2)	06/27/2029	Common Shares	41,322	$5.39	D
Share Option (right to buy)	(2)	06/25/2030	Common Shares	34,562	$6.95	D
Share Option (right to buy)	(2)	06/24/2031	Common Shares	28,463	$7.23	D
Share Option (right to buy)	(2)	06/23/2032	Common Shares	22,050	$3.15	D
Share Option (right to buy)	(2)	12/31/2032	Common Shares	66,667	$2.03	D
Share Option (right to buy)	(3)	12/31/2033	Common Shares	27,607	$3.99	D
Share Option (right to buy)	(4)	12/31/2034	Common Shares	61,538	$2.91	D
Share Option (right to buy)	(5)	12/31/2035	Common Shares	89,552	$3.03	D

Explanation of Responses:

1. Includes 136,620 common shares underlying outstanding restricted share units.

2. The share option is fully vested.

3. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2024.

4. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2025.

5. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Matthias Maurer, attorney-in-fact for Piergiorgio Donati	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the AC Immune (ACIU) Form 3 filing by Piergiorgio Donati show?

The Form 3 shows Chief Operating Officer Piergiorgio Donati’s existing equity stake in AC Immune SA, including common shares and multiple option awards, establishing his baseline ownership as an insider for future SEC reporting purposes.

How many AC Immune (ACIU) common shares does Piergiorgio Donati report owning?

Piergiorgio Donati reports direct ownership of 141,120 common shares of AC Immune SA. This total includes 136,620 common shares that are issuable under outstanding restricted share units, reflecting both currently held and RSU-linked share interests.

What stock options over AC Immune (ACIU) shares are reported in Donati’s Form 3?

Donati reports several share options over AC Immune common shares with exercise prices from $2.03 to $9.50 and expiration dates between July 2028 and December 2035, indicating long-dated rights to purchase additional shares.

Are any of Piergiorgio Donati’s AC Immune (ACIU) options already vested?

Yes. A footnote states that at least one share option is fully vested. Other option grants will vest in twelve substantially equal quarterly installments, providing gradual vesting over time rather than all at once.

When do Piergiorgio Donati’s AC Immune (ACIU) options begin vesting?

Certain options begin vesting in twelve substantially equal quarterly installments starting on March 31, 2024, with others beginning on March 31, 2025 and March 31, 2026. This creates staggered vesting schedules across multiple award years.

Does the AC Immune (ACIU) Form 3 show any recent buying or selling by Piergiorgio Donati?

The data presented reflect holdings rather than new purchases or sales. Transactions are characterized as holding entries with unknown transaction codes, so the filing mainly establishes Donati’s current equity position, not recent trading activity.